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 Summary
	 Background:  The	 past	 decades	 have	 significantly	 changed	 the	 diagnosis	 and	management	 of	 kidney	 tumors.	
There	 is	 a	 growing	 trend	 for	 a	 less	 invasive	 therapeutic	 approach.	 The	 study	 seeks	 to	 present	
our	 experience	with	 a	number	 of	 patients	who	underwent	 percutaneous	ultrasound	 (US)-guided	
radiofrequency	ablation	(RFA)	of	renal	masses.	
 Material/Methods:  From	July	2002	to	December	2006,	RFA	was	carried	out	in	55	selected	patients	with	an	enhancing	
kidney	 tumor	 on	 computed	 tomography	 (CT).	 The	 procedure	 was	 performed	 under	 conscious	
sedation.	The	patients	were	at	risk	for	surgery	or	had	a	remaining	kidney.	Monopolar	Cool-tip	Tyco	
or	bipolar	Celon	Olympus	RFA	devices	under	US-guidance	(convex	3.5	MHz)	were	used.	Abdominal	
3-phase	multi-slice	computed	tomography	(MSCT)	was	performed	3,	6	and	12	months	post	RFA	and	
once	yearly	thereafter.	
	 Results:	 At	a	mean	follow	up	of	25	months	 (range,	6-53	months),	52	of	the	55	tumors	showed	no	contrast	
enhancement	on	CT.	Three	incompletely	ablated	tumors	were	successfully	treated	with	the	second	
RFA.	There	were	no	major	complications	in	any	procedure	and	intervention	was	well	tolerated.	So	
far	we	have	observed	one	metastasis	to	a	homolateral	adrenal	gland	which	was	revealed	on	MSCT.		
	 Conclusions:  Percutaneous	RFA	is	a	minimally	invasive	technique	which	appears	to	be	a	promising	alternative	
for	 patients	 with	 small	 renal	 tumors.	 3-phase	 MSCT	 improves	 the	 imaging	 of	 renal	 masses,	
enabling	not	only	optimal	treatment	planning	but	also	a	reliable	monitoring	of	tumor	destruction	
after	RFA.
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Background
The	past	decades	have	changed	significantly	 the	diagnosis	
and	management	of	renal	tumors.	With	the	introduction	of	
multi-slice	computed	tomography	(MSCT)	and	development	
of	magnetic	resonance	imaging	(MRI)	 (phased-array	multi-
coils,	fast	breath-hold	imaging)	in	the	last	few	years,	more	
than	50	%	of	kidney	tumors	are	discovered	incidentally	and	
many	of	them	represent	an	early	stage	lesion	[1].	This	gives	
an	increasing	need	for	less	invasive	treatment	options	i.e.,	
laparoscopic	partial	 nephrectomy,	 radiofrequency	ablation	
or	 cryoablation	 [2].	Minimally	 invasive	 techniques	 (MIT)	
have	been	developed	to	achieve	two	aims:	to	preserve	renal	
function	 and	 to	 lower	 morbidity.	 Modern	 ablative	 tech-
niques	 for	 renal	 tumors	 include	mainly	 cryoablation	 and	
radiofrequency	 ablation	 (RFA).	RFA	 involves	 inducing	 the	
coagulative	necrosis	of	 tumor	tissue	via	needle	electrodes.	
RFA	 is	 currently	 performed	with	 the	 use	 of	 open	 gantry	
MRI,	CT	scan	or	US.	At	most	centers,	renal	masses	are	not	
routinely	 biopsied	before	 surgical	 removal	 because	 of	 the	
risk	of	tumor	seeding	and	the	possibility	of	a	false-negative	
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	pathological	result	[2].	Therefore,	preoperative	diagnosis	is	
commonly	based	 on	 imaging	 findings	 only	 [3].	At	 present,	
our	 indication	 for	RFA	of	 renal	 tumors	 is	 limited	 only	 to	
strictly	 selected	 patients	 who	 would	 be	 at	 operative	 or	
anesthetic	risk	or	who	have	a	remaining	kidney.	Currently,	
the	use	of	MIT	is	being	increasingly	advocated	for	the	man-
agement	of	small	(<4	cm)	renal	tumors,	not	only	in	patients	
who	 are	 unfit	 for	 surgery	 but	 also	who	 simply	 prefer	 to	
avoid	the	conventional	surgical	approach.
Materials and methods
From	July	2002	 to	December	2006,	 58	RFA	procedures	 in	
55	 selected	patients	with	kidney	 tumors	were	performed.	
The	average	tumor	size	was	36	mm	(range,	18-59	mm)	with	
a	mean	age	of	67	years	(range,	28-83	years).	6	patients	were	
over	 80	 years	 old.	 Most	 of	 the	 diagnosed	 kidney	 tumor	
candidates	 had	 contraindications	 to	 surgery;	 some	 of	 the	
patients	with	a	remaining	kidney	did	not	accept	nephrecto-
my	and	chronic	dialysis.	In	our	group,	15	patients	had	one	
kidney	only	and	2	had	cancer	recurrence	in	the	remaining	
kidney	after	the	nephron-	sparing	surgery	(NSS)	made	seve-
ral	years	ago.	Kidney	tumors	were	localized	out	of	the	renal	
sinus,	frequently	in	a	lower	pole	near	the	exterior	renal	sur-
face	(tab.	1).	Eligibility	for	RFA	was	based	on	abdominal	US	
and	abdominal	MSCT	generating	16	x	0.5	mm	slices	with	
each	half-second	gantry	rotation,	the	Aquilion	Toshiba	with	
workstation	 Vitrea	 2.	 The	 patients	 underwent	 non-con-
trast	MSCT	and	contrast-enhanced	examinations	after	 the	
injection	of	100	ml	of	non-ionic	contrast	medium	at	a	flow	
rate	of	2.5-4.5	ml/s	at	the	arterial	and	parenchymal	phases.	
The	 three-dimensional	 (3D)	 images	were	 taken	using	axial	
scans	MPR	 (Multiplanar	Reconstruction),	MIP	 (Maximum	
Intensity	Projection)	and	VR	 (Volume	Rendering).	 In	every	
case	 the	 contrast	 enhancement	 of	 tumor	 of	more	 than	20	
Hounsfield	units	 (HU)	was	described	 in	CT.	Needle	 biopsy	
was	made	 only	 3	 times,	where	 there	was	 a	 suspicion	 of	
angiomyolipoma.	Monopolar	Cool-tip	Tyco	or	bipolar	Celon	
Olympus	RFA	devices	 under	US-	 guidance	 (convex	 3.5	M	
Hz)	were	used.	Only	 2	 procedures	were	 carried	 out	with	
bipolar	RFA.	RFA	was	performed	under	conscious	sedation	
with	local	anesthesia	and	consisted	of	1	or	2	punctures	of	a	
single	 straight	RFA	probe,	 depending	 on	 tumor	perimeter.	
We	made	a	US-guided	puncture	in	an	attempt	to	obtain	a	5	
to	7	mm	safe	margin	of	normal	renal	parenchyma	in	order	
to	 avoid	 skip	 areas	 and	 to	 obtain	 oncological	 efficacy.	 For	
small	 lesions	<	3	 cm,	 one	puncture	 of	 an	RFA	probe	was	
enough	 to	 coagulate	neoplastic	 tissue.	 For	 lesions	>	3	 cm	
before	starting	ablation	we	placed	2	straight	probes	within	
1	cm	of	each	other.	Afterwards	RFA	by	means	of	 the	 first	
and	 then	 the	 second	 probe	was	 performed.	 The	 ablation	
was	 stopped	 after	 reaching	 a	 temperature	 of	 70°C	 in	 the	
center	 of	 the	 lesion	 and	 the	 procedure	was	 finished	with	
tract	ablation	 in	order	 to	prevent	hemorrhage.	The	avera-
ge	RFA	 time	was	 between	10	 and	 15	minutes,	 depending	
on	the	size	of	the	tumor.	This	was	enough	to	receive	tissue	
necrosis.	The	coagulated	tumor	was	left	in	situ	and	was	not	
examined	 histopathologically.	 All	 patients	 received	 anti-
biotics	 for	 5	 days	 and	 a	painkiller	 –	 paracetamol	 -	where	
necessary.	Treatment	 efficacy	was	 assessed	by	MSCT	3,	 6	
and	 12	months	 post	RFA	 and	 once	 yearly	 thereafter.	 The	
absence	of	contrast	enhancement	on	CT	was	considered	to	
confirm	a	successful	treatment.
Results
The	average	follow-up	was	25	months	(range,	6-53	months)	
(tab.	1).	 52	 tumors	 (94.5%)	underwent	 total	 tissue	necrosis	
after	the	only	procedure	and	3	(5.5%)	after	the	second	abla-
tion	 session	 –	RFA	 -	was	 repeated	 in	 these	 cases	 because	
of	incomplete	tumor	destruction	after	the	initial	treatment.	
3	lesions	which	demanded	repetition	of	RFA	were	>	34	mm,	
mean	 size	=	47	mm.	Lesions	<	34	mm	showed	no	enhan-
cement	 in	CT	after	the	only	RFA.	There	were	no	complica-
tions	following	51	of	the	procedures,	including	every	RFA	in	
small	(<	3.5	cm)	exophytic	renal	tumors.	In	4	interventions	
complications	 included	 (tab.	1):	 2	 patients	with	 tempora-
ry	 increase	 in	 serum	creatinine	 and	urea	 level	with	up	 to	
38.5°C	fever,	1	patient	with	anuria,	hyperkaliemia	and	ura-
emia	which	demanded	 temporary	dialysis	 and	1	with	neu-
ralgy	diagnosed	later	as	shingles.	There	were	no	hemorrhage	
or	bowel	complications	in	any	of	the	cases.	Currently,	all	the	
patients	are	alive	and	there	is	no	need	for	a	chronic	dialysis	
for	any	of	those	cases	with	the	remaining	kidney.	In	the	fol-
low-up	 in	 1	 patient	we	 observed	 a	metastasis	 to	 a	 homo-
lateral	 adrenal	 gland.	The	 gland	was	 removed,	 the	 kidney	
with	the	coagulated	tumor	was	assessed	during	the	surgical	
procedure	 and	 its	 tissue	was	 examined	histopathologically	
-	no	viable	cancer	cells	were	detected.	
Discussion
Percutaneous	 radiofrequency	 ablation	 (pRFA)	 has	 demon-
strated	 encouraging	 results	 as	 a	minimally	 invasive	 and	
safe	 technique	 for	 the	 treatment	 of	 small	 renal	 tumors	
[4,	5].	 Hospital	 stay	 and	 costs	 are	 often	 reduced	 because	
of	a	quick	 recovery	 [6].	RFA	can	be	even	performed	 in	an	
outpatient	 basis.	Moreover,	 in	 case	 of	 incomplete	 tumor	
destruction	it	may	be	safely	repeated	(3	times	in	our	group).	
The	most	 common	complications	 include	pain	 and	pares-
thesis.	Other	complications,	such	as	perinephric	haemato-
mas,	 transient	haematuria,	ureteropelvic	 junction	obstru-
ction,	 colon	 injury,	 and	 liver	 burns,	 have	been	described	
[7,	8,	9].	We	had	no	major	complication.	 In	our	opinion,	a	
metastasis	 to	 a	homolateral	 adrenal	 gland	does	not	 seem	
to	be	related	to	our	procedure	and	was	more	probably	due	
to	the	systemic	disease	progression	rather	than	the	spread	
of	cancer	cells	from	the	ablated	area.	Because	the	ablated	
renal	tumor	is	 left	 in	situ,	 it	 is	not	available	for	complete	
pathological	 evaluation.	Hence,	 definitive	histopathologi-
cal	confirmation	about	the	diagnosis,	margins	and	comple-
teness	of	tumor	cell	killing	cannot	be	obtained	after	pRFA	
[10].	These	issues	have	led	many	investigators	to	perform	
percutaneous	 biopsy	 before	 or	 in	 conjunction	 with	 an	
ablation	procedure.	In	our	cases,	needle	biopsy	was	made	
only	3	times,	where	there	was	a	suspicion	of	angiomyoli-
poma.	The	needle	 biopsy	 of	 a	 small	 lesion	 is	 not	 helpful	
in	differentiating	benign	 from	malignant	 tumors,	 as	most	
solid	masses	are	composed	of	a	heterogeneous	population	
of	 cells	 and	 sampling	 errors	 are	 common.	 For	 effective	
ablation,	the	temperature	within	the	neoplastic	mass	sho-
uld	 exceed	70°C	 [11].	We	 finished	RFA	after	 reaching	 this	
	temperature.	
At	present,	the	only	imaging	modality	to	observe	the	lesion	
in	 real	 time	 remains	MRI;	RFA	 causes	 a	 predictable	 loss	
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Table 1. Characterization of patients and tumors undergoing radiofrequency ablation (RFA).
Patient 
no.
lesion 
mm
only 
kidney Kidney&Location Age Other informations Complications
F-U 
months
1 35 x left, lower, mid, exophytic 64 2 RFA procedures, incomplete tumor destruction after 1 RFA 53
2 30 x left, upper, mid exopytic 67 temporary dialysis 42
3 18 right, lower, mid, parenchymal 67 AML, needle biopsy neuralgy, shingles 36
4 29 right, lower, mid, exophytic 72 needle biopsy, right kidney tumor with liver metastasis 24
5 45 x left, mid, exophytic 50 36
6 50 x right, lower, mid, exophytic 40 33
7 47 left, lower, mid, exophytic 52 33
8 40 right, lower, mid, parenchymal 61 42
9 27 x right, lower, mid, exophytic 58 increase in serum 
creatinine level, fever
21
10 43 left, upper, mid exopytic 83 33
11 50 x right, lower, mid, exophytic 72 tumor recurrence after NSS 27
12 40 right, lower, mid, exophytic 83 21
13 46 x right, lower, mid, exophytic 79 30
14 46 left, lower, exophytic 71 36
15 55 x left, upper, mid exopytic 57 24
16 26 right, lower, exophytic 28 AML, needle biopsy 30
17 51 left, lower, mid, exophytic 83 Parkinson disease 18
18 51 left, mid, parenchymal 59 NYHA 3 30
19 59 x left, lower, mid, exophytic 72 2 RFA procedures, metastasis to adrenal gland,  
incomplet tumor destruction
42
20 34 right, upper, exopytic 68 30
21 41 right, upper, exopytic 82 Aneurysma Aortae Abdominalis 30
22 47 left, mid, parenchymal 74 18
23 27 right, upper, exopytic 65 27
24 43 right, lower, mid, exophytic 83 30
25 35 right, mid, exophytic 75 30
26 28 right, lower, mid, exophytic 77 left kidney cirrhosis 21
27 33 left, mid, exophytic 65 after chemotherapy of tumor of ovary 18
28 31 left, lower, mid, exophytic 82 45
29 31 left, upper, exopytic 79 27
30 38 x right, mid, exophytic 73 increase in serum 
creatinine level, fever
30
31 24 right, upper, exopytic 65 27
32 18 x left, lower, exophytic 68 30
33 47 right, upper, exopytic 75 2 RFA procedures, incomplete tumor destruction after 1 RFA 24
34 30 left, lower, mid, exophytic 61 30
35 34 x right, upper, exopytic 59 21
36 40 left, mid, exophytic 76 18
37 28 right, upper, exopytic 68 30
38 42 x left, lower, mid, parenchymal 76 27
39 33 x left, mid, exophytic 68 30
40 29 right, lower, parenchymal 59 33
41 47 left, upper, exopytic 73 18
42 34 right, mid, exophytic 76 24
43 32  left, upper, exophytic 79   15
44 30 left, lower, exophytic 41 15
45 30 left, lower, exophytic 73 coronary artery disease 9
46 37 right, upper, exopytic 67 9
47 30 right, lower, exopytic 71 9
48 44 right, lower, exopytic 77 9
49 22 left,  lower 50 tumor recurrence after NSS 9
50 31 left, upper, exophytic 55 9
51 28 x right, upper, exopytic 72 9
52 18 right, upper, exopytic 43 9
53 25 right, upper, exopytic 78 6
54 20 left, mid, exophytic 34 AML, needle biopsy 6
55 53 left, mid, exophytic 73
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of	T1	 signal	 [12,	13,	14].	However,	 there	 is	 only	 a	 limited	
opportunity	 to	perform	RFA	under	MRI	guidance.	Follow-
up	 after	 renal	 ablative	 therapy	 remains	 controversial.	
There	 is	 no	 perfect	 tool	 for	 detecting	 recurrences.	 The	
absence	 of	 contrast	 enhancement	 on	CT	does	not	 exclude	
the	presence	of	viable	cancer	cells.	The	results	of	some	stu-
dies	 showed	 an	 absence	 of	 total	 tumor	necrosis	 and	pre-
sence	 of	neoplastic	 cells	 after	 ablation	 [15,	16].	The	deve-
lopment	of	MSCT	has	improved	detection,	characterization	
and	 the	 staging	 of	 small	 renal	 tumors.	MSCT	 eliminates	
respiratory	misregistration,	 decreases	 the	 partial	 volume	
effect,	 allows	 for	 image	 acquisitions	 during	 optimal	 con-
trast	 enhancement	 and	 is	widely	 available.	Accurate	 ima-
ging	of	a	patient	with	suspected	renal	cell	carcinoma	(RCC)	
requires	 a	 combination	 of	 sequences.	Many	different	pro-
tocols	 have	 been	 described	 in	 the	 literature	 [17,	18,	19].	
Un-enhanced	CT	 scans	 are	 required	 to	 identify	 calcifica-
tion.	Accurate	analysis	of	renal	masses	requires	the	use	of	
an	 intravenous	contrast	medium	which	 is	associated	with	
a	risk	 of	 contrast	 reaction	 and	 is	 potentially	 nephrotoxic.	
The	ability	of	MRI	to	characterize	renal	masses	has	impro-
ved,	but	protocols	vary	widely	and	usually	include	pre-	and	
post-contrast	images	[20,	21].	The	use	of	gadolinium	or	CO	(2)	
as	alternative	contrast	media	 to	avoid	 the	 risk	of	nephro-
toxicity	cannot	be	substantiated	by	clinical	 trials	and	the-
refore	 cannot	 be	 recommended.	 Moreover,	 gadolinium-
based	 contrast	media	 can	 cause	 contrast	medium-induced	
nephropathy	even	at	doses	below	0.2	mmol/kg	body	weight	
in	patients	with	multiple	risk	factors	[22].
Conclusions
Percutaneous	RFA	is	a	minimally	invasive	technique	which	
seems	to	represent	an	attractive	and	promising	alternative	
for	patients	with	small	renal	tumors.	Using	3-phase	MSCT	
has	significantly	improved	the	imaging	of	renal	mass,	inclu-
ding	 not	 only	 optimal	 treatment	 planning	 but	 a	 reliable	
monitoring	of	tumor	destruction	after	RFA.
	 1.	Sheth	S,	Fishman	EK.	Multi-detector	row	CT	of	the	kidneys	and	
urinary	tract:	techniques	and	applications	in	the	diagnosis	of	benign	
diseases.Radiographics.	2004	Mar-Apr;	24(2):	e20.
	 2.	Mouraviev	V,	Joniau	S,	Van	Poppel	H,	Polascik	TJ.	Current	status	
of	minimally	invasive	ablative	techniques	in	the	treatment	of	small	
renal	tumours.	Eur	Urol.	2007	Feb;	51(2):	328–36.	
	 3.	Gervais	DA,	McGovern	FJ,	Arellano	RS,	McDougal	WS,	Mueller	PR.	
Radiofrequency	ablation	of	renal	cell	carcinoma:	part	1,	Indications,	
results,	and	role	in	patient	management	over	a	6-year	period		
and	ablation	of	100	tumors.	AJR	Am	J	Roentgenol.	2005	Jul;		
185(1):	64–71.
	 4.	Arzola	J,	Baughman	SM,	Hernandez	J,	Bishoff	JT.	Computed	
tomography-guided,	resistance-based,	percutaneous	radiofrequency	
ablation	of	renal	malignancies	under	conscious	sedation	at	two	years	
of	follow-up.	Urology.	2006	Nov;	68(5):	983–7.
	 5.	Park	S,	Anderson	JK,	Matsumoto	ED,	Lotan	Y,	Josephs	S,	Cadeddu	
JA.	Radiofrequency	ablation	of	renal	tumors:	intermediate-term	
results.	J	Endourol.	2006	Aug;	20(8):	569–73.
	 6.	Link	RE,	Permpongkosol	S,	Gupta	A,	Jarrett	TW,	Solomon	SB,	
Kavoussi	LR.	Cost	analysis	of	open,	laparoscopic,	and	percutaneous	
treatment	options	for	nephron-sparing	surgery.	J	Endourol.	2006	
Oct;	20(10):	782–9.
	 7.	Gervais	DA,	Arellano	RS,	McGovern	FJ,	McDougal	WS,	Mueller	PR.	
Radiofrequency	ablation	of	renal	cell	carcinoma:	part	2,	Lessons	
learned	with	ablation	of	100	tumors.	AJR	Am	J	Roentgenol.	2005	
Jul;	185(1):	72–80.
	 8.	Weizer	AZ,	Raj	GV,	O'Connell	M,	Robertson	CN,	Nelson	RC,	Polascik	
TJ.	Complications	after	percutaneous	radiofrequency	ablation	of	
renal	tumors.	Urology.	2005	Dec;	66(6):	1176–80.
	 9.	Pavlovich	CP,	Walther	MM,	Choyke	PL,	Pautler	SE,	Chang	R,	Linehan	
WM,	et	al.Percutaneous	radio	frequency	ablation	of	small	renal	
tumors:	initial	results.	J	Urol.	2002	Jan;	167(1):	10–5.
	 10.	Permpongkosol	S,	Link	RE,	Solomon	SB,	Kavoussi	LR.	Results	of	
computerized	tomography	guided	percutaneous	ablation	of	renal	
masses	with	nondiagnostic	pre-ablation	pathological	findings.		
J	Urol.	2006	Aug;	176(2):	463–7.
	 11.	Rehman	J,	Landman	J,	Lee	D,	Venkatesh	R,	Bostwick	DG,	Sundaram	
C,	Clayman	RV.Needle-based	ablation	of	renal	parenchyma	
using	microwave,	cryoablation,	impedance-	and	temperature-
based	monopolar	and	bipolar	radiofrequency,	and	liquid	and	gel	
chemoablation:	laboratory	studies	and	review	of	the	literature.	
J	Endourol.	2004	Feb;	18(1):	83–104.	Review.	
	 12.	Tacke	J,	Mahnken	AH,	Gunther	RW.	Percutaneous	thermal	ablation	
of	renal	neoplasms.	Rofo.	2005	Dec;	177(12):	1631–40.	Review.
	 13.	Anderson	JK,	Shingleton	WB,	Cadeddu	JA.	Imaging	associated	with	
percutaneous	and	intraoperative	management	of	renal	tumors.	Urol	
Clin	North	Am.	2006	Aug;	33(3):	339–52.	Review.
	 14.	Svatek	RS,	Sims	R,	Anderson	JK,	Abdel-Aziz	K,	Cadeddu	JA.	
Magnetic	resonance	imaging	characteristics	of	renal	tumors	after	
radiofrequency	ablation.	Urology.	2006	Mar;	67(3):	508–12.
	 15.	Rendon	RA,	Kachura	JR,	Sweet	JM,	Gertner	MR,	Sherar	MD,	
Robinette	M,	et	al.:The	uncertainty	of	radio	frequency	treatment	
of	renal	cell	carcinoma:	findings	at	immediate	and	delayed	
nephrectomy.J	Urol.	2002	Apr;	167(4):	1587–92.
	 16.	Matlaga	BR,	Zagoria	RJ,	Woodruff	RD,	Torti	FM,	Hall	MC.	Phase	II	
trial	of	radio	frequency	ablation	of	renal	cancer:	evaluation	of	the	
kill	zone.	J	Urol.	2002	Dec;	168(6):	2401–5.
	 17.	Jinzaki	M,	McTavish	JD,	Zou	KH,	Judy	PF,	Silverman	SG.	Evaluation	of	
small	(</=	3	cm)	renal	masses	with	MDCT:	benefits	of	thin	overlapping	
reconstructions.	AJR	Am	J	Roentgenol.	2004	Jul;	183(1):	223–8.
	 18.	Beer	AJ,	Dobritz	M,	Zantl	N,	Weirich	G,	Stollfuss	J,	Rummeny	EJ.	
Comparison	of	16-MDCT	and	MRI	for	characterization	of	kidney	
lesions.	AJR	Am	J	Roentgenol.	2006	Jun;	186(6):	1639–50.
	 19.	Catalano	C,	Fraioli	F,	Laghi	A	et	al.	High-resolution	multidetector	CT	
in	the	preoperative	evaluation	of	patients	with	renal	cell	carcinoma.	
AJR	Am	J	Roentgenol.	2003	May;	180(5):	1271–7.
	 20.	Kalinka	A,	Gerlach	A,	Arlart	IP	et	al.	Characterization	and	staging	
of	renal	tumors:	significance	of	MRI	diagnostics.	Rofo.	2006	Mar;	
178(3):	298–305.
	 21.	Boss	A,	Martirosian	P,	Schraml	C,	et	al.	Morphological,	contrast-enhanced	
and	spin	labeling	perfusion	imaging	for	monitoring	of	relapse	after	RF	
ablation	of	renal	cell	carcinomas.	Eur	Radiol.	2006	Jun;	16(6):	1226–36.	
	 22.	Thomsen	HS.	Nephrogenic	systemic	fibrosis:	A	serious	late	adverse	
reaction	to	gadodiamide.	Eur	Radiol.	2006	Dec;	16(12):	2619–21.
References:
